Table 1 General characteristic of the study subjects.

From: MiR-323b-5p acts as a novel diagnostic biomarker for critical limb ischemia in type 2 diabetic patients

 

miRNA array cohort

P

validation cohor

P

CLI

Non - CLI

CLI

Non - CLI

No. of subjects

4

4

—

27

31

—

Age, y

65.00 ± 1.73

65.50 ± 1.55

0.837

64.30 ± 2.73

61.0, (56.0–69.0)

0.790‡

T2D Duration, y

10.00 ± 1.41

12.25 ± 1.80

0.363

15.48 ± 1.47

9.0, (8.0–14.0)

0.004 ‡

Women, %

2, (50.00)

2, (50.00)

1.000

14, (51.85)

16, (51.61)

0.986†

Hyperlipidemia, %

0, (0)

2, (50.00)

0.429

10, (37.04)

10, (32.26)

0.702†

Hypertension, %

2, (50.00)

2, (50.00)

1.000

16, (59.26)

9, (29.03)

0.020 †

Smoking, %

2, (50.00)

2, (50.00)

1.000

15, (55.56)

8, (25.81)

0.021 †

ABI

0.46 ± 0.10

1.06 ± 0.03

0.007

24.10 (22.70–25.80)

1.11 ± 0.01

0.000 ‡

BMI, kg/m2

23.80 ± 1.21

25.98 ± 1.99

0.386

24.95 ± 0.57

25.46 ± 0.52

0.512

CAD, %

2, (50.00)

2, (50.00)

1.000

8, (29.63)

8, (25.81)

0.745†

Statin use, %

0, (0)

1, (25.00)

1.000

6, (22.22)

4, (12.90)

0.349†

Antihypertensive treatment use, %

2, (50.00)

1, (25.00)

1.000

8, (29.63)

5, (16.13)

0.219†

FPG, mmol/L

8.27 ± 2.69

7.87 ± 1.52

0.899

9.60 (8.65–14.36)

7.27 (6.14–9.05)

0.001 ‡

HbA1c, %

10.35 ± 1.15

7.48 ± 0.31

0.509

8.90 (7.90–9.60)

6.90 (6.50–9.00)

0.001 ‡

HDL-C, mmol/L

0.97 ± 0.08

1.06 ± 0.06

0.372

1.08 ± 0.05

1.16 (0.90–1.32)

0.281‡

LDL-C, mmol/L

2.14 ± 0.16

3.10 ± 0.41

0.100

2.63 ± 0.17

2.63 ± 0.15

0.987

TG, mmol/L

1.29 ± 0.33

1.37 ± 0.45

0.901

1.48 (1.07–1.86)

1.29 (0.92–1.84)

0.847‡

TC, mmol/L

3.51 ± 0.23

4.69 ± 0.42

0.048

2.80 (2.55–3.68)

4.30 ± 0.18

0.006 ‡

Apo A, g/L

1.09 ± 0.07

1.19 ± 0.04

0.248

1.16 (1.03–1.29)

1.15 (1.06–1.35)

0.172‡

Apo B, g/L

0.80 ± 0.06

0.96 ± 0.10

0.194

0.92 ± 0.04

0.86 ± 0.04

0.265

Cr, μmol/L

55.50 ± 6.36

72.75 ± 9.58

0.184

75.00 (58.00–107.00)

65.00 (55.00–72.00)

0.044 ‡

BUN, mmol/L

4.95 ± 0.93

6.24 ± 1.06

0.393

5.60 (4.60–7.24)

6.11 ± 0.40

0.374‡

UA, mmol/L

268.00 ± 10.96

262.25 ± 39.80

0.897

327.97 ± 13.45

323.76 ± 18.77

0.860

Total bilirubin, mol/L

11.63 ± 1.48

10.03 ± 1.71

0.586

12.51 ± 0.97

12.50 ± 0.87

0.995

hsCRP, mg/dL

1.24 ± 0.69

0.64 ± 0.25

0.446

0.35 (0.19–1.36)

0.64 (0.26–2.30)

0.402‡

ALT, U/L

18.00 ± 7.53

22.00 ± 5.02

0.674

14.60 (8.00–26.00)

14.00 (10.90–23.00)

0.343‡

AST, U/L

21.75 ± 3.78

22.50 ± 2.72

0.877

19.00 (13.00–31.00)

19.28 ± 1.25

0.136‡

  1. ABI, Ankle brachial index; BMI, body mass index; CAD, coronary artery disease; FPG, fasting plasma glucose; HbA1c, glycosylated hemoglobin; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; TG, triglyceride; TC, total cholesterol; Apo A, Apolipoprotein A; Apo B, Apolipoprotein B; Cr, serum creatinine; BUN, blood urea nitrogen; UA, uric acid; hsCRP, high-sensitivity C-reactive protein; ALT, alanine aminotransferase; AST, aspartate aminotransferase. Data is expressed as mean ± SEM, median (interquartile range) or percentage. Significant values are marked in italic. Continuous variales were compared by the Fisher-Pitman Permutation test, and categorical variables were compared by Fisher’s exact test in the miRNA array cohort, however, the validation cohort was analyzed using †χ2 test or ‡Mann-Whitney U-test, and the others were analyzed using t-tests.
Back to article page